Information Provided By: 
Fly News Breaks for July 17, 2018
LLY, XERS
Jul 17, 2018 | 06:24 EDT
Mizuho analyst Difei Yang last night initiated coverage of Xeris Pharmaceuticals with a Buy rating and $26 price target. The company offers a potentially superior solution for the treatment of severe hypoglycemia compared to the standard of care - Eli Lilly's (LLY) glucagon emergency kit, Yang told investors in a research note. The analyst sees a "significant growth opportunity" for the ready-to-use glucagon rescue pen as more healthcare professionals prescribe an easier option for patients with diabetes at risk of severe hypoglycemia.
News For XERS;LLY From the Last 2 Days
LLY
Apr 19, 2024 | 12:01 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
LLY
Apr 19, 2024 | 06:17 EDT
